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The effects of equiblocking doses of three beta-adren-
ergic blocking agents, propranolol, timolol and meto-
prolol, on myocardial infarct size were evaluated in 28
dogs after acute experimental coronary artery occlusion.
Heart rate, arterial pressure and arterial free fatty acid
concentration were measured in an attempt to evaluate
their effects on the extent of myocardial injury. The zone
at risk of infarction in each dog 1 minute after left an-
terior coronary artery occlusion was assessed by inject-
ing highly radioactive albumin microspheres into the left
atrium, and the hypopedused zone was determined by
autoradiography.
After 15 minutes, the dogs were randomized into four
groups: control dogs (n=7), propranolol-treated dogs
(1.2 mg/kg intravenously, n = 7), timolol-treated dogs
(0.2 mg/kg intravenously, n = 7) and metoprolol-treated
dogs (1.2 mg/kg intravenously, n = 7). After 6 hours,
Beta-adrenergic receptor blockade is one of the most prom-
ising interventions for the protection of the ischemic myo-
cardium. The oldest and most studied agent, propranolol,
has been shown in the experimental animal to minimize the
electrocardiographic (1,2), enzymatic (1), metabolic (3) and
histologic and ultrastructural (4,5) manifestations of myo-
cardial ischemic damage. Similarly, the electrocardio-
graphic variables of ischemic damage were reduced and the
metabolic profile improved by the administration of pro-
pranolol to patients with acute myocardial infarction (6,7).
Recently, several studies (8-11) have shown beneficial ef-
fects of beta-adrenergic blockade in preventing sudden car-
diac death and reinfarction after acute myocardial infarction.
Because of the great variability in the extent of infarction
after experimental coronary artery occlusion in animals, a
comparison of the efficacy of different drugs in reducing
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the dogs were killed. The left ventricle was sliced and
stained with triphenyl-tetrazolium chloride for mea-
surement of infarct size. The same slices were then au-
toradiographed for measurement of the hypopedused
zone. The percent of hypopedused zone that evolved to
infarction (the ratio of infarct size to hypopedused zone)
was 90.4 ± 1.9% in the control group, 72.4 ± 2.4% in
the propranolol-treated dogs (p < 0.05 versus control
group); 57.9 ± 4.4% in the timolol-treated dogs (p <
0.01 versus control group; p < 0.05 versus propranolol)
and 54.4 ± 3.7% in the metoprelol-treated dogs (p <
0.01 versus control group; p < 0.05 versus propranolol).
Thus, propranolol, timolol and metoprolol reduced
myocardial infarct size in dogs by 20, 36 and 40%, re-
spectively,after experimental coronary artery occlusion.
Metoprolol and timolol protected the ischemic myocar-
dium more effectively than did propranolol.
myocardial infarct size has, until recently, not been possible
(12). The purpose of this investigation was to use a newly
developed experimental technique to measure myocardial
infarct size to study and compare the effects of the three
most commonly used beta-adrenergic blocking agents, pro-
pranolol, timolol and metoprolol. Since hemodynamic al-
terations and fatty acid metabolism are factors that may
modulate the extent of myocardial injury in the early phase
of an infarction (1,13), measurements of the heart rate,
arterial pressure and plasma concentration of free fatty acids
were also done.
Methods
Animal preparation. Thirty-nine dogs of either sex,
weighing between 17 and 29 kg, were anesthetized with
pentobarbital (25 mg/kg body weight intravenously), intu-
bated endotracheally and ventilated with a Harvard respi-
rator. The heart was exposed through a thoracotomy in the
fifth intercostal space and suspended in a pericardial cradle.
In preparation for occlusion, the left descending coronary
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artery was dissected free from the adjacent tissue immedi-
ately above the first diagonal branch, A polyethylene cath-
eter was placed in the left atrium through an incision in the
atrial appendage for injection of radioactive-labeled micro-
spheres. A second catheter was placed in the left carotid
artery to monitor the systemic arterial pressure and a third
was placed in the jugular vein for administration of drugs
and fluids. Systemic arterial pressure measurements using
a Statham P23Db pressure transducer and electrocardio-
graphic (lead aVF) tracings were recorded continuously on
a multichannel recorder (Gould Instruments).
Experimental protocol. The left anterior descending
coronary artery was occluded by a ligature. One minute
later, 2.10 6 highly radioactive (8 mCi) technetium-
99m-Iabeled albumin microspheres (20 JLm diameter) were
injected into the left atrium for assessment of the hypoper-
fused zone (14).
Fifteen minutes after coronary artery occlusion. the dogs
were randomized into four groups: Group I, control (n = 7);
Group II, propranolol-treated (1.2 mg/kg intravenously as
a bolus) (n =7); Group III, timolol-treated (0.2 mg/kg in-
travenously as a bolus) (n =7) and Group IV, metoprolol-
treated (1.2 mg/kg intravenously as a bolus) (n = 7). Each
drug was administered in 10 ml of saline solution over a 5
minute period. Six hours after coronary artery occlusion,
the animals were killed. The heart was excised and the left
ventricle dissected free from the right ventricle, valves,
atria, great vessels and adipose tissue. After freezing at
-70°C, the left ventricle was sliced into 3 mm thick trans-
verse sections in a plane parallel to the atrioventricular groove.
Determination of area at risk for development of ne-
crosis. To assess the hypoperfused zone of the myocardium
(the area at risk of infarction), the slices underwent auto-
radiography by placement on a high speed X-ray film (Cro-
nex-4, E.I. Dupont) (12,14). By this technique, areas with
normal perfusion appear as "hot spots," while the hypo-
perfused areas appear as "cold spots." To clearly identify
the border of the slices, a "soft" X-ray film (that is. 25
kilivolt pressure, 100 milliampere-second) was obtained
and superimposed on the autoradiograph. Both the total area
of the slices and the area of hypoperfusion were traced on
transparent plastic sheets and calculated by planimetry. Areas
that showed hypoperfused zones smaller than 15% of the
left ventricle were excluded because it has been shown that
in dogs with small areas of hypoperfusion, treatment results
in more extensive reduction in infarct size (15).
Determination of myocardial infarct size. To deter-
mine the extent of myocardial necrosis, the slices were
incubated in a 1% solution of triphenyl-tetrazolium chloride
(ITC, Sigma Chemical Company) for 10 minutes at 37°C
(16,17). Then they were immersed in a 10% solution of
formalin. Infarcted myocardium appeared as yellow areas,
while normal myocardium stained dark red. The normal
myocardium and infarcted areas were then traced on trans-
parent plastic sheets and the areas measured by planimetry.
Isoproterenol sensitivity testing. To test the degree of
beta-adrenergic blockade, heart rate measurements with dif-
ferent doses of isoproterenol were recorded in 19 dogs at
the end of the 6 hour experiment. In four control dogs, five
propranolol-treated dogs, three timolol-treated dogs and seven
metoprolol-treated dogs, isoproterenol in doses of 0.1, 0.2
and 0.4 JLg/kg was infused for I minute per dose. The heart
rate was measured before and after each infusion. At the
completion of the experiment, the dogs were killed.
Biochemical analysis. Arterial blood samples for mea-
surement of free fatty acids and glucose were collected in
precooled heparinized tubes and the plasma separated by
centrifugation. Plasma concentrations of free fatty acids were
assayed using a colorimetric method (19). Glucose concen-
trations were determined by a glucose oxidase method using
a commercial kit (Sigma Chemical Company).
Calculations. The extent of the hypoperfused zones, as
shown by autoradiography, was expressed as a percent of
the total left ventricular area. The extent of the infarcted
myocardium, as shown by staining with triphenyl-tetrazo-
lium chloride, was expressed as a percent of the total left
ventricular area. The percent of the hypoperfused zone that
evolved into necrosis was expressed by the ratio: infarct
size/hypoperfused zone x 100% (12,14,15).
Statistics. All data were expressed as mean ± standard
error of the mean. A paired Student's t test was used to
evaluate the changes within each group. Dunnetts' method
was used to evaluate differences between control and treat-
ment groups, while a protected least significant difference
procedure was used to test for differences among different
mean values (20). For evaluation of continuous data during
the experimental period, data from the whole experimental
period in the different groups were compared.
Results
Twenty-eight of 39 dogs were suitable for analysis, with
7 dogs in each of the four groups. Four dogs were excluded
before randomization because of ventricular fibrillation or
hypotension. After randomization, the exclusions were: two
dogs with ventricular fibrillation (one in the propranolol-
treated and one in the metoprolol-treated group), three dogs
with hypoperfused zones less than 15% of the left ventricle
and two dogs with technically poor autoradiographs. At the
time of randomization (that is, 15 minutes after coronary
occlusion), the control dogs and the dogs in the treated
groups did not differ significantly from each other relative
to heart rate, mean arterial pressure or arterial concentrations
of glucose and fatty acids (Table 1).
Hemodynamic effects. Heart rate. In the control
group, heart rate did not change significantly throughout the
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Table 1. Hemodynamic and Metabolic Values at Randomization 15 Minutes After Coronary
Artery Occlusion
Propranolol Timolol Metoprolol
Control (1,2 mg/kg) (0,2 mg/kg) (1,2 mg/kg)
Heart rate (beatslmin) 144 ± II 136 ± 9 151 ± 9 135 ± 8
Mean arterialpressure (mm Hg) 99 ± 9 96 ± 6 96 ± 6 89 ± 5
ArterialFFA concentration (IA-moi/liter) 310 ± 82 272 ± 33 274 ± 45 313 ± 42
Arterial glucoseconcentration (mmoi/liter) 6,3 ± 0.4 6,1 ± 0.4 6,2 ± 0,4 5,6 ± 0.2
Data are expressedas mean ± standarderror of the mean. FFA = free fatty acid.
molol- (p < 0.01, n =7) and metoprolol-treated groups
(p < 0.05, n =7) lasted for the whole experimental period,
and the reductions were significant.
Arterial pressure. Mean arterial pressure was not sig-
nificantly changed in the control group (Fig. 1). In the
propranolol-treated group, mean arterial pressure increased
after 180 to 300 minutes (p < 0.05), and for the whole
experimental period the increase was significant (p < 0.05).
In the metoprolol-treated group, the increase in mean arterial
pressure at 240 minutes (p < 0.05) and 300 minutes (p <
0.05) was significant, but not when analyzed for the whole
experimental period. Timolol did not significantly change
mean arterial pressure.
Isoproterenol response. The heart rate response to iso-
proterenol infusion for 1 minute with doses of 0.1, 0.2 and
0.4 p.g/kg was similar in propranolol-, timolol- and meto-
prolol-treated dogs, but was significantly lower than in the
control group (p < 0.05).
Metabolic effects. The increase in arterial free fatty acid
concentrations in the control group reached a maximal value
at 180 minutes, and the increase offatty acid concentrations
for the whole period was significant (p < 0.05). All three
beta-adrenergic blocking agents reduced the fatty acid con-
centrations after 60 minutes: propranolol by 52 ± 17
p.mol/liter (p < 0.05), timolol by 85 ± 25 p.mollliter
(p < 0.01) and metoprolol by 136 ± 32 p.moUliter (p <
0.01) (Fig. 2). A lowering of fatty acid concentrations for
the whole treatment period was observed only in the me-
toprolol-treated group (p < 0.05). The arterial glucose con-
centrations were not changed during the experimental period
for either the control group or any of the drug-treated groups.
Zone of hypoperfusion, The distance from the ostium
of the coronary artery to the site of occlusion was 2.5 ±
0.1 ern in the control group, 2.5 ± 0.1 em in the propran-
olol-treated group, 2.7 ± 0.2 em in the timolol-treated
group and 2.4 ± 0.1 em in the metoprolol-treated group.
These distances were not different among the groups.
The zone ofhypoperfusion, assessed I minute after coro-
nary artery occlusion by autoradiography, was similar in all
groups with 20.8 ± 1.4% of the left ventricle in the control
group, 23.6 ± 0.8% in the propranolol-treated group, 24.0
± 2.0% in the metoprolol-treated group and 26.2 ± 2.0%
Figure 1. Changes in heart rate (LHR, top) and mean arterial
pressure (LAP, bottom) during coronary artery occlusion in con-
trol (open circles, n = 7), propranolol-treated (closed circles, 1.2
mg/kg intravenously, n = 7), timolol-treated (open squares, 0.2
mg/kg intravenously, n ~ 7) and metoprolol-treated dogs (closed
squares, 1.2 mg/kg intravenously, n = 7). *p<0.05 and **p<O.OI
versus values 15 minutes after coronary artery occlusion.
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experimental period (Fig. 1). The heart rate decreased sig-
nificantly after 60 minutes in dogs treated with propranolol
(by 21 ± 5 beats/min, p < 0.01), timolol (by 27 ± 3
beats/min, p < 0.01) and metoprolol (by 22 ± 9 beats/min,
p< 0.05). The reduction in heart rate in the propranolol-
treated group lasted for only 180 minutes and was not sig-
nificantly reduced when analyzed for the whole experimen-
tal period. However, the reduction in heart rate in the ti-
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Figure 2. Changes in arterial free fatty acid concentrations (D.
FFA) during coronary artery occlusion. Symbols as in Figure I.
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Figure 3. Effects on myocardial infarct size relative to hypoper-
fused zone (lS/HZ. %). Symbols as in Figure I.
tened the resolution of these electrocardiographic abnor-
malities (1,2). Propranolol also caused a reduction in myo-
cardial creatine kinase depletion after 24 hours of occl usion
(I) , the histologic and ultrastructural appearance of cell
injury (4-5) and the anatomic size of the infarcted myo-
cardium (21). In contrast, it was reported (22) that pro-
pranolol did not reduce myocardial creatine kinase depletion
when given in a dose of 5 mg/kg . Timolol was also shown
to reduce epicardial ST segment elevation (23) and anatomic
infarct size assessed by tetrazolium staining (24) in cats .
Metoprolol was shown to reduce enzyme release in ischem-
ically perfused rat hearts (25). In clinical studies (6,26,27),
propranolol and metoprolol were shown to reduce myo-
cardial damage by electrocardiographic criteria, that is, a
reduction in ST segment elevatio n and a smaller decrease
in R wave voltage or smaller development of Q waves .
Reduction of myocard ial injury by propranolol and timolo l
was also shown (28,29) using serum creatine kinase dis-
appearance curves.
Determination of myocardial infarct size. In the pres-
ent investigation , it was demon strated that all three beta-
adrenergic blocking agent s significantly reduced the percent
of the hypoperfused zone that evolved to necrosis . Pro-
pranolol caused a 20% decrease. timolol a 36% decrease
and metoprolol a 40% decrease . The technique used in this
study measures infarct size by using the triphenyl-tetrazo-
lium chloride stain to anatomically define the infarct and
planimetry to measure it. The advantage of using the hy-
poperfused zone in each dog to predict the extent of necrosis
is that each animal has a different anatomic distribution of
coronary arteries as well as a different anastomotic collateral
circulation. Therefore, by calculating the ratio of infarct
size to hypoperfused zone, the variability is obviated and
the results can be verified using a rather small number of
dogs. This was demonstrated in the present study. If the
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Discussion
Previous studies. The favorable effects of the beta-ad-
renergic blocking agents on myocardial infarct size, as found
in this study, are in accordance with earlier experimental
and clinical studies that used indirect techniques to show
reduction in acute myocardial ischemia. Propranolol is the
beta-adrenergic blocking agent that has been most exten-
sively evaluated in previous experimental studies. When
given before coro nary artery occl usion, propranolol dimin-
ished the height of epicardial and precordial ST segment
elevations . When given after occlusion, propranolol has-
in the tirnolol-treated group. The extent of the zones at risk
of infarction were thus comparable before treatme nt.
Myocardial infarct size. Infarct size, expressed as per-
cent of left ventricle, was significa ntly smaller in metopro-
101- (13.4 ± 1.5%, P < 0.05) and timolol-treated dogs
(14.9 ± 1.3%, P < 0.05) than in the control dogs (18.8
± 1.4%). Propranolol did not change infarct size signifi-
cant ly (17.0 ± 0.7%, p = NS). The percent of the hy-
poperfused zone that evolved to infarction was as follows:
in the control group, an average of 90.4 ± 1.9% of the
hypoperfused zone evolved to necrosis; in the three drug-
treated groups, the value was significantly reduced to 72.4
± 2.4% in the propranolol-treated dogs (p < 0.05), 57.9
± 4.4% in the timolol-treated dogs (p < 0.01) and 54.4
± 3.7% in the metoprolol-treated dogs (p < 0.01). The
reductions in the percent of the hypoperfused zone that
evolved to necrosis were significantly larger for timolol- (p
< 0.05) and metoprolol - (p < 0.05) than for propranolol-
treated dogs . Thus, compared with the control dogs, the
ratio of infarct size to hypoperfused zone was reduced by
20% with propra nolol, 36% with timolo l and 40% with
metoprolol (Fig . 3).
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effect iveness of a drug such as timolol or metoprolol is
significant, then it will reduce infarct size, even without
normalization . However , when a less potent drug such as
propranolol is used, the less exact technique does not result
in a statistical difference with the number of dogs in this
study . When infarct size is normalized by the zone at risk
of infarction, the reduction in myocardial damage was sig-
nificant for all three drugs .
Other advantages of this technique are: I) The zone at
risk (If infarction is determined in vivo and. thus, expresses
the actual zone of hypoperfu sion at real hemodynamic con-
dition s in the dog, including the collateral flow. 2) The zone
of hypoperfusion is measured after coronary artery occlusion
but before randomization and, thus , before any treatment.
This measurement is, therefore, not influenced by the effect
of the drugs, as may be the case when the hypoperfused
zone is determined at the end of the experiment. 3) As
measured in these experiments, over 90% of the zone of
hypoperfusion evolves to necrosis and its extent accurately
pred icts the extent of necrosis (12-1 5).
Thus, using this quantitati ve techniqu e it was possible to
study the effect iveness of each of the three beta-adrenergic
blocking agents and compare their effectiveness in reducing
infarct size. The question of whether these agents actually
prevent necrosis or just delay it was not addressed in this
investigation. The effect of each drug on infarct size was
studied after 6 hours of coronary artery occlusion using the
triphenyl-tetrazolium chloride staining technique (16,17),
which is based on the deplet ion of dehydrogenase from the
injured myocardium. Nevertheless. this depletion is closely
related to ultrastructural changes consistent with severe
myocardial injury (30) . It also has been reported (21,24)
that beta-adrenergic blocking agents have shown their ef-
fectivene ss even when infarct size was measured 24 hours
after coronary artery occlusion. Moreover, interventions such
as hyaluronidase were found to be effective in reducing
infarct size in both rats and dogs killed 21 days after coro-
nary artery occlusion (31,32).
Possible mechanisms of action. The exact mechanisms
of action of the beta-adrenergic blocking agents are un-
known, but several possible mechanisms might be dis-
cussed. These include I) reduction in myocardial oxygen
consumption due to blockad e of beta-adrenergic receptors,
2) blockade of sympathetic nervous activity, 3) changes of
substrate utilization , 4) augment ation of collateral blood
flow, 5) reduction in microvascular injury. and 6) stabili-
zation of cell membranes.
f) Reduction in myocardial oxygen consumption. The
most widely held view is that beta-adrenergic blocking drugs
preserve ischem ic myocardial tissue by reducing myocardial
oxygen demand secondary to both the negative inotropic
and chronotropic effects. The effect of propranolol is only
partly due to decreasing heart rate . When propranolol was
given to dogs with coronary artery occlusion while heart
rate was maintained by constant electrical stimulation , a
significant decrease in ST segment elevation still occurred
(1).
2) Blockade of sympathetic nervous activity. A second
possible mechanism is related to propranolol 's ability to
block not only beta-adrenergic receptors, but also sympa-
thetic nervous activity. Although the manner in which pro-
pranolol produces this effect is not clear, it has been reported
(7) that propranolol decreases plasma catecholamine con-
centrations during evolution of myocardial infarction in pa-
tients, a finding consistent with the possibility that pro-
pranolol reduces sympathetic nerve impulse traffic .
3) Changes of substrate utilization. The third possibility
is that beta-adrenergic blockade may influence the concen-
tration of fatty acids, both locally and systemically. High
fatty acid supply to the heart has been shown to increase
myocardial oxygen consumption in the normal heart (33)
and to enhance myocardial ischemic damage in experimental
studies (34.35). Conversely, a reduct ion of fatty acid supply
to the heart has been shown to reduce myocardial oxygen
consumption by approx imately 25% (36,37) and to sub-
stantially reduce the extent of acute myocardial ischemic
injury (38). Lipolysis in adipose tissue is mediated by beta-
adrenergic receptors (39). In our study, propranolol , timolol
and metoprolol all significantly reduced arterial fatty acid
concentrations, suggesting a depressed myocardial fatty acid
metabolism. Thus, both in patients with myocardial infarc-
tion (7) and in dogs with coronary occlusion (3), propranolol
shifts myocardial metabolism from mainly fatty acids to
carbohydrates . causing lactate production to revert to ex-
traction , which results in reduced myocardial oxygen
consumption.
Catecholamines might have a local deleterious effect on
the ischemic myocardium. Noradrenaline was shown (40)
to be released within the ischemic region seconds after coro-
nary occlusion. This local adrenergic stimulation induces
intracellular lipolysi s with local fatty acid release within the
ischemic myocardium (4 1,42). Evidence is accumulating
for the existence of a detr imental metabol ic fatty acid-tri -
glyceride cycle in the ischem ic myocardium with wasting
of energy (13,42) and which probably is inhibited by beta-
adrenergic blockade (43).
4) Augmentation of collateral flow. A fourth hypothesi s
maintains that propranolol improves oxygen supply by in-
creasing coronary collateral flow. Some studies (44,45) have
shown an improvement in collateral flow to the ischemic
myocardium or a relative redistribut ion of flow favoring the
ischemic subendocardium. Other studies (46) have not shown
this or have actualIy shown a reduct ion in colIateral blood
flow. This discrepancy may be related to the animals' state
of consciousness . An increase in collateral flow to the isch-
emic myocardium was shown in conscious dogs (45), while
no such effect was observed in anesthetized dogs (46). How-
ever, because the studies that showed a reduction in ischemic
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injury were performed in anesthetized animals, it is unlikely
that the preservation of the myocardium is due to an increase
in coronary collateral flow.
5) Reduction in microvascular injury. The fifth hypoth-
esis is a primary protective effect on the microvasculature.
It has been demonstrated that propranolol not only decreases
ischemic myocardial cell damage, but also reduces ischemic
microvascular damage (5). However, since significant mi-
crovascular injury occurs only after myocardial cell injury,
it appears unlikely that the beta-adrenergic blocking agent's
primary action is through protection of the microvascula-
ture. Nonetheless, this protective action on the microvas-
culature, even if secondary, might still be of some biologic
importance.
Possible explanations for the difference in potency
among beta-blocking agents. The reason for the greater
protection against ischemic injury by metoprolol and timolol
than by propranolol is not clear. Several possible expla-
nations might, however, be discussed. 1) There are some
pharmacologic differences among the drugs besides their
common ability to block beta-adrenergic receptors (47). Of
the three, metoprolol is the only selective beta-blocking
agent, while propranolol and timolol are nonselective betar-
and betaj- receptor blockers. In high doses. metoprolol and
propranolol have membrane-stabilizing activity. while ti-
molol does not. None of the three beta-blocking agents has
intrinsic sympathomimetic activity. Therefore, there is no
common pharmacologic property of metoprolol and timolol
which differs from that of propranolol.
2) The degree of beta-adrenergic blockade may be dif-
ferent. Timolol was shown to have six times greater potency
than propranolol or metoprolol (47), and the doses of the
three beta-blocking agents were adjusted accordingly. Fur-
thermore, it was recently found that timolol uniquely in-
terferes with the intracellular mobilization of calcium (48).
In the present study, the heart rate response to isoproterenol
given intravenously at the end of the experiment (after 6
hours) was similarly significantly lower for all three drug-
treated groups than for the control group. This similarity is
consistent with an equal degree of beta-receptor blockade.
The differences in response in the ischemic myocardium
cannot, therefore, merely represent a variable degree of
beta-adrenergic blockade.
3) Although the dose chosen for all three beta-blocking
agents produced a substantial reduction in heart rate, this
reduction tended to be less for propranolol than for either
timolol or metoprolol throughout the experimental period.
Furthermore, the decrease in heart rate caused by propran-
olol was not sustained throughout the 6 hour experimental
period and there was a trend toward baseline after 4 hours.
This could be a consequence of the slightly shorter half-life
of propranolol (49) when compared with that oftimolol (50)
and metoprolol (51).
4) The metabolic effects ofpropranolol, as evidenced by
the reduction in arterial fatty acid concentration, were also
less marked than those of metoprolol in this study. Thus,
myocardial oxygen consumption was probably reduced to
a lesser extent with propranolol than with the other two
drugs. This may partially explain why propranolol had a
less favorable effect on infarct size reduction than did ti-
molol or metoprolol.
Clinical implications. The extrapolation of these results
to the clinical setting should be done only with the utmost
caution because animal models mimic only certain char-
acteristics of the human pathologic condition. However, it
is noteworthy that all three beta-adrenergic blocking agents
were effective in reducing myocardial damage and that
quantitatively the effects of timolol and metoprolol were
very significant. Whether these two agents will also be more
effective than propranolol in patients is unknown since a
species difference in the effectiveness of these drugs may
exist.
We thank Barbara B Whiteside for typing the manuscript and Sharon L.
Kasdin, MD for editorial assistance.
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